2019 American Society of Clinical Oncology Annual Meeting*

Download All
May 31 - June 4, 2019; Chicago, Illinois
Review slidesets and analyses of key data from the 2019 Oncology meeting.

Lung Cancer

Capsule Summary Slidesets

Treatment with ICI-based therapy showed comparable safety and no significant differences in clinical efficacy for patients with vs without a history of autoimmune disease.

Released: June 6, 2019

AMG 510 showed a tolerable safety profile and preliminary antitumor activity in previously treated patients with KRASG12C-positive tumors, including NSCLC.

Released: June 5, 2019

TAK-788 achieved 43% confirmed ORR in patients with previously treated advanced NSCLC and EGFR exon 20 insertion mutations.

Released: June 11, 2019

BLU-667, a selective and potent RET inhibitor, achieved a high response rate with durable responses in patients with RET+ NSCLC regardless of prior treatment.

Released: June 4, 2019
Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an educational grant from
Blueprint Medicines

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.